KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Receivables for 18 consecutive years, with $884.0 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables rose 111.46% year-over-year to $884.0 million; the TTM value through Mar 2026 reached $884.0 million, up 111.46%, while the annual FY2025 figure was $777.6 million, 91.85% up from the prior year.
  • Receivables hit $884.0 million in Q1 2026 for Alnylam Pharmaceuticals, up from $777.6 million in the prior quarter.
  • Across five years, Receivables topped out at $964.8 million in Q3 2025 and bottomed at $9.1 million in Q2 2022.
  • Average Receivables over 5 years is $367.6 million, with a median of $321.4 million recorded in 2024.
  • Year-over-year, Receivables tumbled 98.3% in 2022 and then surged 2331.51% in 2023.
  • Alnylam Pharmaceuticals' Receivables stood at $32.3 million in 2022, then surged by 207.88% to $99.6 million in 2023, then surged by 307.03% to $405.3 million in 2024, then surged by 91.85% to $777.6 million in 2025, then rose by 13.68% to $884.0 million in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $884.0 million, $777.6 million, and $964.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.